10 Things Worth Pay...
Health Care: Drugs
Ariad Pharmaceuticals (ARIA: NASDAQ)
$15.63 -0.08 | -0.51%
06/04/12 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 15.71 |
| 52 Week High | 17.60 |
| 52 Week Low | 7.55 |
| Avg. Daily Vol. (Mil) | 3.39 |
| Beta (3 year) | 1.75 |
| Share Related Items | |
| Mkt Cap (Mil) | 2,603.60 |
| Shares Out (Mil) | 165.73 |
| Float (Mil) | 136.85 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 9.90 |
| Current Ratio | 10.00 |
| LT Debt/ Equity | 0.04 |
| Total Debt / Equity | 0.05 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 102.80 |
| Price/Book | 10.12 |
| Price/Cash Flow | -19.00 |
| Per Share Data | |
| Earnings | -0.99 |
| Sales | 0.15 |
| Book Value | 1.55 |
| Cash Flow | -0.83 |
| Business Summary | |
|---|---|
| Ariad Pharmaceuticals Inc is engaged in the discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules. | |
| General Information | |
| 26 Landsdowne Street
Cambridge, MA 02139 |
|
| www.ariad.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 150 | |
| CEO: Dr. Harvey J. Berger,M.D | |
| Short Interest | |
| Current Month (Mil) | 13.44 |
| Previous Month (Mil) | 14.16 |
| Short Interest Ratio (Days) | 3.80 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -46.60 |
| Return on Investments | -52.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with ARIA
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- Contributor7 Cancer Drug Stocks to Kno...
- ContributorStocks At New 52-Week Highs...
- ContributorStocks Rising On Unusual Vo...
- Contributor10 Biotech Stocks Loved and...
- ContributorEarnings Short Squeeze Play...
- Contributor5 Stocks Under-$10 Setting ...
- Userlance and donna
- ContributorHot Biotech Trades for Seco...
Latest ARIA Headlines from TheStreet
- ASCO 2012 Live Blog -- Monday 06.04.12 | 06:06 am
- ASCO '12: Ariad Pharma Leukemia Drug Posts Improved Response Rates 06.04.12 | 12:06 am
- Biotech Stock Mailbag: ASCO, Celldex, Obesity Drug Game-Changer 05.25.12 | 05:05 am
- The Next Big Thing in Biotech: ASCO Conference
05.25.12 | 05:05 am - ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) 05.17.12 | 06:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus 05.16.12 | 06:05 pm
- Ariad Stock Hits New 52-Week High (ARIA) 05.11.12 | 01:05 pm
- Ariad Reaches New 52-Week High (ARIA) 04.27.12 | 11:04 am
- Endocyte Shares Rise on Merck Cancer Deal 04.16.12 | 09:04 am
- Analysts' Actions: ARIA, EA, HGSI, BBBY 04.12.12 | 08:04 am
Press Releases for ARIA
- ARIAD Announces Updated Data From Pivotal PACE Trial Of Ponatinib, Its Investigational Pan-BCR-ABL Inhibitor - Business Wire 06.04.12 | 07:06 am
- ARIAD To Present At Upcoming Investor Conferences - Business Wire 05.30.12 | 07:05 am
- ARIAD To Present At Bank Of America Merrill Lynch 2012 Health Care Conference - Business Wire 05.10.12 | 07:05 am
- ARIAD To Present At The Deutsche Bank 37th Annual Health Care Conference - Business Wire 04.30.12 | 07:04 am
- ARIAD To Webcast Conference Call On First Quarter 2012 Financial Results - Business Wire 04.25.12 | 07:04 am
- ARIAD Presents New Preclinical Data On Ponatinib And AP26113 - Business Wire 04.02.12 | 09:04 am
- ARIAD Announces Presentations Of Preclinical Data At American Association For Cancer Research Annual Meeting - Business Wire 03.26.12 | 07:03 am
- Merck And ARIAD Pharmaceuticals Provide Update On FDA Advisory Committee Vote On Investigational Medicine Ridaforolimus For The Treatment Of Metastatic Soft-Tissue Or Bone Sarcomas - Business Wire 03.20.12 | 07:03 pm
- ARIAD To Present At Barclays Capital Global Healthcare Conference - Business Wire 03.06.12 | 07:03 am
- ARIAD Reports 2011 Financial Results And Outlines Key Development And Commercialization Plans For 2012 - Business Wire 02.28.12 | 07:02 am
Partner Headlines for ARIA
- AACR Annual Oncology Meeting: A Look Into Various Abstracts - Seeking Alpha 03.27.12 | 09:03 am
- Zacks #5 Rank Additions for Thursday - Tale of the Tape - Zacks 03.22.12 | 09:03 am
- Zacks #5 Rank Additions for Wednesday - Tale of the Tape - Zacks 03.14.12 | 09:03 am
- Zacks #5 Rank Additions for Tuesday - Tale of the Tape - Zacks 02.28.12 | 09:02 am
- Notable Put Options Activity in ARIAD Pharmaceuticals - Benzinga 02.02.12 | 01:02 pm
- Biotech Equities Continue To Benefit From Discoveries And Acquisitions In 2012 - Seeking Alpha 01.27.12 | 09:01 am
- 10 Stocks That Made New Highs On Friday: Hedging Costs - Seeking Alpha 01.15.12 | 07:01 am
- Using Friday's Option Trades To Find Investment Ideas - Seeking Alpha 01.13.12 | 06:01 pm
- YM's Positive Results Have Incyte Investors Worried - Seeking Alpha 12.15.11 | 09:12 am
- Rodman & Renshaw Maintain Market Outperform Rating and $15 PT on ARIAD Pharmaceuticals - Benzinga 11.01.11 | 09:11 am
